Pharmaxis tumbles on FDA rejection of Bronchitol in CF
This article was originally published in Scrip
Executive Summary
Given the unanimous snub it got in January from a US FDA panel of advisers, it came as little surprise regulators rejected Pharmaxis' new drug application for Bronchitol, an experimental dry-powder mannitol medicine, as a treatment to improve pulmonary function in patients as young as 6 years with cystic fibrosis (CF).